A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

NCT03901469 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

115

Enrollment

INDUSTRY

Sponsor class

Stopped Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: ZEN003694
DRUG: Talazoparib

Sponsor

Zenith Epigenetics

Collaborators

[object Object]
[object Object]